Teva's Q2 2026 revenue fell 1%, operating income fell $686M and the shares rose 8.6%. All three follow from one subtraction the release never performs: US generics lost $301M in the quarter, and three branded products added $306M.
Witfire Elite · CMC & Manufacturing Risk Brief · Case No. 2026-06 The CMC Execution Crisis: Why Unicycive’s Second CRL Is a Warning Shot…
Witfire Elite Pharma News Investments Stock Market Breaking Analysis 28.3 Pharma Market Case Study · Witfire Elite View Eli Lilly Retatrutide Phase 3 Results…
Witfire Elite Investment Case Studies Strategy Investment News Investment Witfire Elite View Lilly’s Germany Investment Cut Why Pharma Capital Is Starting to Vote Against…
